Tips for Abstract Submission

*Deadline to Submit is February 2, 2022 at 5:00 PM CST*

To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate category.

Full list of abstract categories:
- Adherence to Guidelines
- Appropriateness/Efficiency of Care
- Behavioral/ Psychosocial Factors
- Cardiac Arrest/CPR
- Cardiovascular Registries
- Clinical Trials – Main Results and Substudies
- Coronary Artery Disease (CAD) (New!)
- Cost Effectiveness Analysis/Economic Assessment
- Data Science
- Disparities in Care (Health inequities)
- Health Information Technology
- Implementation Science
- International Research (Studies Outside the US)
- Medication Adherence
- Methodology of Outcomes Research
- Older Adults and Cardiovascular Aging
- Outcomes (New!)
- Patient Experience/Satisfaction
- Pattern of Care Description
- Policy Research
- Population Health
- Quality Improvement Initiatives – Local Level
- Quality Improvement Initiatives – Regional/National Level
- Quality of Care Assessment
- Quality of Life/Functional Status Assessment
- Stroke
- Risk Factor Assessment and Treatment
- Risk Stratification and Prognosis
- Valvular Heart Disease (New!)
- Women and Cardiovascular Disease
- Other

**Abstract Submissions:**
- Submit all abstracts in English.
- Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
- Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
- Proofread abstracts carefully to avoid errors before submission. The abstract will be reviewed exactly as submitted. Edits cannot be made after submission.
- An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.
- Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
- Use generic drug names.
- Do not begin sentences with numerals.
- Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.

Revised 12/07/2021
• Do not include references, credits or grant support.
• Do not include the names or personal information of any patient participating in the study or trial.
• The body of the abstract must not exceed 1,950 characters (not including spaces). The addition of a graphic deducts 250 characters. Graphic files should only include one image per file.

Acceptance
• Submitters will be notified of acceptance/non-acceptance status via e-mail by late-February 2022.
• Abstracts are reviewed in blinded fashion and selected on the basis of scientific merit. The conference Program Committees will determine whether the abstract is to be presented orally or by poster.
• Request oral or poster preferred presentation on the Presentation Preference tab of the Submitter Site. The selection of one of these options will neither prejudice acceptance nor guarantee an oral or poster presentation because abstracts will be arranged to fit into a thematic group for presentation. Although every effort will be made to accommodate your presentation request, there is no guarantee that you will present in the mode of your preference unless you specify “poster only”.
• Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter.
• Presenting/submitting authors must register and pay associated fees for attendance at the conference.
• Abstracts selected will be posted on the AHA Web sites of the Council on Quality of Care and Outcomes Research.
• Accepted abstracts will not have been published (manuscript or abstract) prior to the date and time of presentation or presented at any national or international meeting prior to May 13, 2022. Abstracts are embargoed for release at date and time of presentation or time of AHA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.
• Submission of an abstract constitutes a commitment by the authors to present if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts.
• Recording Policy:

  * Author(s) understands that the AHA plans to record and videotape and/or duplicate selected presentations or video interviews from Quality of Care and Outcomes Research, at which the Author(s) will be a speaker, abstract presenter or volunteer participant. Author(s) agrees that AHA may record Author(s) in both audiotape and videotape during this event, and may use Author(s) name, likeness, image, voice, appearance and performance, as well as the images or files that may include posters and presentation slides that are a part of Author(s) presentation (hereafter “Recorded Presentation”), in such recording and in any media.

  Author(s) hereby assigns all rights, title and interest and copyright ownership in and to the Recorded Presentation to the AHA to use, reproduce, edit, alter, copy, exhibit, sell, distribute, and display for any purpose and Author(s) waive any right to inspect or approve the Recorded Presentation in which Author(s) likeness may be used or reproduced or to claim any rights to any income realized by AHA or others.

  Further, Author hereby grants a non-exclusive, non-transferable, license in and to Author’s presentation slides and posters to the AHA to use, reproduce, edit, alter, copy, exhibit, sell, distribute, and display for any purpose and Author(s) waive any right to inspect or approve the Recorded Presentation in which Author(s) likeness may be used or reproduced or to claim any rights to any income realized by AHA or others.

Abstract Withdrawal
There is no guarantee that your abstract will not be published in the final program unless the request for withdrawal is received in writing by 5:00 PM, March 15, 2022.

Abstract Revisions
Proofread abstracts carefully to avoid errors before submission. No proof pages will be sent to authors.

Revised 12/07/2021
Presentation

- All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
- References to work previously published by other authors must include citations at the bottom of the appropriate slides.
- Unauthorized recording of the conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting a/v materials and of poster presentations and supporting poster materials.
- All oral presentations must be in electronic format. Electronic presentations must be submitted 2 hours in advance of the session start time. Instructions will be provided upon acceptance.
- No 35 mm slides will be presented at the conference.

Abstracts Copyright Transfer Agreement

During the abstract submission process, you will have the opportunity to provide your approval (electronically) of the copyright transfer agreement.

Your approval of this agreement indicates:

- The author(s) hereby assigns, conveys, and otherwise transfers all rights, title, interest and copyright ownership in said work to the AHA/ASA effective upon acceptance of said work for presentation. “Work” includes the material submitted for presentation and any other related material submitted to the AHA/ASA.
- The assignment of rights to the AHA/ASA includes, but is not expressly limited to, rights to edit, publish, reproduce, distribute copies, prepare derivative works, include in indexes or search databases in print, electronic, or other media, whether or not in use at the time of execution of this agreement, and claim copyright in said work throughout the world for the full duration of the copyright and any renewals or extensions thereof.

The assignment of rights hereunder does not extend to the full length article on which the abstract is based.

- Author(s) retain the right to subsequently include the work in articles, books or derivative works that he/she authors or edits provided said use does not imply the endorsement of the AHA/ASA.
- Other uses or reproductions require permission from the AHA/ASA, which shall not be unreasonably withheld.
- Author(s) hereby represents and warrants that he/she/they is/are sole author(s) of the work, that all authors have participated in and agree with the content and conclusions of the work, and that the work is original and does not infringe upon any copyright, proprietary, or personal right of any third party.
- If the AHA/ASA does not publish said work, author(s) will be notified and all rights assigned hereunder will revert to author(s).
- If a joint work, all co-authors must transfer rights in said work to the AHA/ASA by executing this Agreement.
- This Agreement must be executed as is without revision or substitution of terms. A handwritten signature of the author(s) is required.
- This Agreement is governed by the laws of the United States of America.
- For U.S. Government Employee Author(s):
  The author(s) hereby warrants that the above-described work was authored by employees of the United States Government as part of their official duties and therefore may be published and reproduced without restriction.

Visit the conference website for additional details on the 2022 conference. We look forward to seeing you in Reston, VA!

Questions?
Contact the QCOR Conference Manager for questions related to your abstract submissions.

Revised 12/07/2021